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LOW RISK PROSTATE CANCER: ACTIVE TREATMENT OR 
ACTIVE SURVEILLANCE?
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SUMMARy – The widely used screening for prostate cancer with prostate specific antigen has 
resulted in identification of potentially lethal prostate cancers at a much more curable stage and has 
been associated with significant falls in prostate cancer mortality. In spite of the fact that prostate 
cancer is one of the deadliest malignancies in men, the advent of sensitive diagnostic testing has also 
resulted in detection of low risk cancers due to the high incidence of latent prostate cancer in aging 
men and prolonged natural history of the disease. This, in turn, has entailed the problem of cancer 
overdiagnosis and subsequent overtreatment. Approximately 6 times as many men will be diagnosed 
with the disease as will die from it. Active surveillance appeared as a response to the clearly docu-
mented risks of overdiagnosis and overtreatment of low risk prostate cancer for localized prostate 
cancer. It entails initial expectant management rather than immediate therapy, with ‘curative-intent’ 
treatment deferred until there is evidence that the patient is at an increased risk of disease progres-
sion. This approach attempts to balance the risks and side effects of overtreatment against the pos-
sibility of disease progression and lost opportunity for cure. A systematic literature review brings 
current knowledge on the subject.
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Introduction
The natural history of prostate cancer is highly 
variable and can range from indolent to very aggressive 
disease. Lifetime risk of acquiring the disease is 16%-
20% and the risk of dying is about 3%1. It is obvious 
that there is great difference between the incidence 
and mortality. Autopsy studies have shown that the 
incidence of prostate cancer in men who died of other 
causes is by far greater than the incidence of clinically 
manifest prostate cancer in the population2,3. The best 
approach to treatment of localized prostate cancer re-
mains a controversial issue4.
The Problem of Early Detection and Overdiagnosis
The wide use of prostate specific antigen (PSA), 
which was introduced in clinical practice in the 1990s, 
has revolutionized early detection of prostate cancer. 
Its use has resulted in detection of a larger number 
of prostate cancers and significant increase in the in-
cidence of this disease. In addition, modified biopsy 
protocols with an increased number of biopsy cores 
have also resulted in a higher rate of cancer detec-
tion. The reduction of mortality by up to 40% in some 
countries is a possible result of earlier detection and/
or better treatment of this disease5. However, a par-
allel unwanted phenomenon is detection of indolent 
cancers, which do not pose threat to the patient health 
and life, and without measures of early detection they 
would never have clinical manifestations. Conse-
quently, a large number of patients are undergoing 
treatment that does not bring any benefit to them, and 
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the complications thus entailed can even reduce their 
quality of life. For these phenomena, excessive diag-
nosis (overdiagnosis) and excessive treatment (over-
treatment) are commonly used terms. The question of 
the benefit of the mass use of PSA for early detection 
of prostate cancer, which in places is reaching the ex-
tent of screening, has failed to be clarified even with 
two randomized, prospective studies, the European 
Randomized Study of Screening for Prostate Cancer 
(ERSPC) and the Prostate, Lung, Colorectal, and 
Ovarian ( PLCO) cancer screening trial6,7. While the 
ERSPC has shown a 27% reduction in mortality (0.73, 
0.61-0.88; p<0.0007), the PLCO study failed to show 
benefit from screening. The objection to the PLCO 
study was the high rate of contamination of PSA test-
ing in the control group, which reached about half of 
the respondents. The objection to screening lies in the 
fact that even with mortality reduction, the screening 
takes a very high price; the latest results of monitor-
ing after 13 years in the ERSPC have shown that it 
is necessary to call 781 men to the screening program 
and to treat 27 men to avoid one death from pros-
tate cancer6. It is believed that the excessive rate of 
diagnosis (overdiagnosis) is around 50% and it is the 
major adverse effect of screening. The use of PSA as a 
screening test has shown all its weaknesses, especially 
low specificity. With a threshold value of 3 ng/mL, 
which was used in the ERSPC, 25% of men aged 55-
69 were ‘positive’, and in the remaining 75% where 
the test was negative (PSA <3 ng/mL), prostate cancer 
was not definitely excluded8.
Active Treatment versus Active Surveillance
When a patient is diagnosed with prostate cancer, 
chances of being actively treated exceed 80% and it is 
very important to distinguish between the potential 
benefits and harms of such approach and understand 
the contemporary population of patients with prostate 
cancer. Although active treatment has contributed to 
reduced prostate cancer mortality in some countries, 
it is important to emphasize that the inclusion of a 
large number of patients with indolent prostate cancer 
(which would do well without treatment) have false-
changed performance statistics of ‘active approach’. 
Direct comparisons of therapeutic modalities for local-
ized prostate cancer with long-term monitoring were 
studied in two multicenter, randomized studies9,10.
In the randomized Scandinavian Prostate Can-
cer Group Study-4 (SPCG-4), which enrolled 695 
patients with localized prostate cancer, mortality 
was compared between the groups subjected to radi-
cal prostatectomy or active control. After 18 years of 
follow up, significant absolute reduction in the rate 
of death from any cause (relative risk (RR)=0.71, 
p<0.001), death rates from prostate cancer (RR=0.56, 
p<0.001) and the risk of metastasis was found in the 
group subjected to radical prostatectomy. Overall, 
there were 13% fewer deaths from any cause and 11% 
fewer deaths from prostate cancer in the group sub-
jected to radical prostatectomy in 18 years of moni-
toring. The effect was limited to men younger than 
65. The absolute risk reduction in total mortality and 
prostate cancer mortality was 25.5% and 15.8%, re-
spectively, in this age group. Among men aged 65 and 
older, radical prostatectomy did not reduce mortality, 
but significantly reduced the risk of metastasis and the 
need of palliative treatment. With longer follow up, 
the number of patients who should have been treated 
to prevent one death from prostate cancer fell to eight. 
The advantage of this study was a randomized and 
prospective design. It provided the highest quality of 
evidence that active treatment saved lives. However, 
it did not provide an answer when to reach for ac-
tive treatment in order to balance the consequences 
and complications of active treatment. Its population 
was heterogeneous and included patients with high, 
medium and low risk. A more detailed analysis shows 
that the most pronounced reduction in mortality 
was among patients with tumors of intermediate risk 
(RR=0.38, p<0.001), while the reduction of mortal-
ity in the two groups with high and low risk was not 
significant (RR=0.54, p=0.17 and RR=0.87, p=0.84, 
respectively). When analyzed according to age, the ef-
fects were more pronounced in men younger than 65, 
suggesting that not only the characteristics of the tu-
mor, but also life expectancy play a role in the choice 
of therapeutic approach. It is important to note that 
the study was initiated in 1989 and that the majority 
of patients came from the so-called ‘pre-PSA’ period. 
Thus, only 5% of patients were T1c stage, and the me-
dian PSA was 13 ng/mL. Given the low proportion of 
patients detected only by elevated PSA, this popula-
tion was very different from the contemporary popu-
lation of patients with prostate cancer. In addition, a 
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restriction of stratifying patients according to the risk 
was that the number of patients in the subgroups was 
too small9. 
Unlike the SPCG-4, the Prostate Cancer Inter-
vention Versus Observation Trial (PIVOT), launched 
in the early era of PSA testing, showed that radical 
prostatectomy for localized prostate cancer was not 
significantly reducing cancer-specific and/or overall 
mortality after 12-year follow up10. PIVOT study 
started in 1994 and compared radical prostatectomy 
with surveillance. Of the 731 respondents, three-
quarters had cancer diagnosed based on elevated 
PSA. Half of the patients had stage T1c disease (only 
elevated PSA, impalpable cancer) and 45% had stage 
T2 disease. The median age was 67 years and median 
PSA 9 ng/mL. About one-third of patients were Afri-
can Americans. Such a mixed population of patients, 
including 45% of low risk, 34% of intermediate risk 
and 21% of high risk patients, was more representative 
of contemporary populations of patients with prostate 
cancer, and inclusion of African Americans is not 
negligible either11. Unlike SPCG-4, this study failed 
to show reduction in the mortality benefit of radical 
prostatectomy for the whole study population. Addi-
tional analysis of the risk groups in the PIVOT study 
showed that in low risk patients (PSA <10, Gleason 
score ≤6), radical prostatectomy did not contribute to 
better overall or disease-specific survival, or the rate 
of progression to metastatic disease. This is a very 
important finding with relevant implications for the 
choice of treatment for low risk cancer. In contrast, in 
higher risk patients (intermediate and high; PSA >10), 
radical prostatectomy resulted in a decrease of total 
(hazard ratio 0.67; 95% CI 0.48-0.94) and cancer-
specific mortality (5.6% vs. 12.8%, p=0.02). However, 
analysis of the intermediate risk group only showed 
reduction in total but not in cancer-specific mortality, 
whereas in the high risk group, cancer-specific mor-
tality was reduced, but not all-cause mortality in fa-
vor of radical prostatectomy12. This result is a possible 
consequence of insufficient power of the study due to 
the small sample11.
In addition, the results of PIVOT may not be 
replicated in younger patients with localized prostate 
cancer. One-third of patients in this study were older 
than 70, and half died before completion of 10-year 
follow up; 85% of deaths were not associated with 
prostate cancer. Therefore, it is difficult to extrapolate 
the PIVOT results to 40% of patients with prostate 
cancer who are diagnosed with the disease before age 
6511,12. Critical analysis points to the fact that due to 
difficulties with patient enrollment, PIVOT failed to 
recruit initially planned 2000 patients and the study 
design was then revised. Only 15% of patients that 
met the inclusion criteria were included in the study9. 
In about one-third of patients there was no appropri-
ate death certificate, so there is certain methodologi-
cal doubt about the use of cancer-specific mortality 
in studies like the PIVOT13. Despite criticisms, some 
analysts suggest that even PIVOT study favors surgi-
cal treatment because 60% less metastases and 37% 
lower mortality were found in the surgical group11.
On considering active treatment versus surveil-
lance, it is necessary to mention radiotherapy as a pos-
sible active approach to patients with localized pros-
tate cancer. Although data are scarce, a randomized 
study that compared these two approaches from the 
pre-PSA era did not demonstrate significant differ-
ences in mortality after 16-year follow up14.
In the light of contradictions in the above mentioned 
studies, it becomes more difficult to recommend an op-
timal approach. The Canadian randomized Standard 
Treatment Against Restricted Treatment (START) 
study was launched in 2007 with the aim to compare 
directly the effectiveness of active treatments and active 
surveillance, but unfortunately, it was stopped for fail-
ing to reach satisfactory inclusion of patients15. Another 
prospective, randomized study that compared the ef-
fectiveness of radical prostatectomy versus radiotherapy 
versus active surveillance in patients with localized 
prostate cancer detected in the PSA era was launched at 
the end of the 1990s in the UK as the Prostate Testing 
for Cancer and Treatment (PROTECT)16. This study 
successfully recruited and tested by PSA over 82,000 
men aged 50-69, with more than 500 respondents in 
each of the three study groups. Compared with the 
PIVOT and SPCG-4, the PROTECT study had 
a lower mean PSA value (5.8 ng/mL), age (61 years), 
higher stage of cancer, and randomized 62% of eligible 
patients (unknown in SPCG-4 and 15% in PIVOT). 
The first results of this study will be published in 2016, 
after 10 years of follow up. They will provide key in-
formation on the approach to patients with localized 
prostate cancer predominantly detected by PSA testing 
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and the potential benefits as well as the potential harm-
ful effects of excessive detection and overtreatment in 
this population.
When to Consider Active Surveillance, When to 
Treat?
It is important to stress that the above mentioned 
studies investigated a heterogeneous group of patients 
with clinically localized prostate cancer but different 
clinical characteristics, represented as low, medium 
and high risk stratification. Contrary, therapeutic ap-
proach to patients with low risk prostate cancer is a 
separate topic. As noted above, the wide use of PSA 
and new protocols of prostate biopsy increased the in-
cidence of prostate cancer, particularly low risk pros-
tate cancer subgroup. This is a homogeneous group, 
although it also failed to be uniformly defined, as 
current possibilities of risk stratification are limited 
by imperfection of the existing methods17. Stratifica-
tion of patients according to the risk level was first 
proposed by D’Amico et al.18, and then the proposed 
division was several times adjusted (Table 1)4,18-20. It is 
estimated that, depending on the prevalence of PSA 
testing in certain areas, up to 45% of newly diagnosed 
patients are eligible for active surveillance18.
Active surveillance means that patients at low risk 
are not treated aggressively (surgery or radiation), but 
are followed by PSA, imaging modalities and repeat 
biopsy, and in the event of disease progression to a 
more aggressive form of prostate cancer, the patient 
is subjected to active treatment with the intention 
to cure. All others in the group are thus spared the 
morbidity of therapeutic procedures of radical pros-
tatectomy or radiation, which is not negligible. It is 
certainly important to distinguish the active surveil-
lance approach from watchful waiting, which for de-
cades has meant observation in the selected group of 
patients with the application of palliative treatment 
in the event of progression. The concept of active sur-
veillance has important implications for patient coun-
seling about their disease, treatment and related qual-
ity of life, and the cost of treatment. The parameters 
defining the patients eligible for active surveillance 
are shown in Table 218,21-28. There are several ongo-
ing studies that follow patients at low risk that have 
been subjected to active surveillance23. Noteworthy is 
that the screening criteria in these studies are quite 
different, just like the criteria for decision on active 
treatment when clinical parameters change during 
follow up. Most studies include low risk cancer (small 
Table 1. Risk groups (adapted from Heidenreich et al.4) 
Very low risk Low risk Intermediate risk High risk
D’Amico18 T1-T2a and GS ≤6 and PSA ≤10
T2b or GS 7 or 
PSA 10-20
≥T2c or PSA 
>20 or GS 8-10
NCCN19
T1c and GS ≤6 and PSA 
<10 and <3 positive cores 
and ≤50% cancer in the 
core
T1-T2a and GS 
2-6 and PSA ≤10
T2b or T2c or 
GS 7 or PSA 
10-20
T3a or PSA >20 
or GS 8-10 T3b-4
CAPSURE20 T1-T2a and GS ≤6 and PSA ≤10 
T2b and/or GS 7 
or PSA >10-20
T3- 4 or PSA 
>20 or GS 8-10
EAU4 GS ≤6 and PSA ≤10 and T1c
T2b-2c and/or 
GS ≤7 and/or 
PSA ≤20
≥T3a or PSA 
>20 or GS 8-10
NCCN = The National Comprehensive Cancer Network; CAPSURE = Cancer of the Prostate Strategic Urologic Research Endeavor; 
EAU = European Association of Urology; GS = Gleason score; PSA = prostate-specific antigen
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volume, low grade, stage and PSA), and some include 
even ‘insignificant’ cancers adding a small number 
of biopsies (<3 or <33%), length of cancer in biopsy 
specimens (<50%), and PSA density (PSAD <0.15 or 
0.20) to the current criteria. The patients are followed 
by PSA, digital rectal examination, and depending on 
the protocol, repeat biopsies are performed after 6 or 
12 months. More recently, increasing importance is 
given to repeat biopsy. The emergence of an increase 
in PSA, unfavorable doubling time of PSA (<2 or 3 
years, depending on the study), and emergence of 
Gleason score 4 or 5 on repeat biopsy reclassify pa-
tients and initiate active treatment at a stage when the 
disease is still curable. Results of one of the studies 
with longest follow up, conducted by Klotz et al. from 
The University of Toronto, showed that one-third of 
patients diverted to active treatment, and the mortality 
from other causes in this cohort was 19 times higher 
than the mortality rate of prostate cancer after 8-year 
follow up23. During the follow up, five of 450 (1.1%) 
patients died from prostate cancer. It is important to 
emphasize that among patients actively treated after 
active surveillance, 50% had biochemical relapse. The 
reason for this may lie in more liberal inclusion crite-
ria in the study (Gleason score 7). The authors of the 
Göteborg randomized trial (part of ERSPC study) 
have recently reported on 442 middle-aged patients 
(65 years of age) under active surveillance who were 
followed-up for 6 years29. An important feature of this 
study is that it included a small number of patients at 
very low (51%), low (26.7%), medium (21%) and high 
(1.4%) risk, and the patient population was significant-
ly different from the modern population under active 
surveillance. In this study, one-third of patients sub-
sequently underwent active treatment, mostly due to 
progression, and only four patients because of anxiety. 
Of the 60 deaths, only one patient died from prostate 
cancer. The patient was under active surveillance for 
8.6 years, and subsequently received androgen depri-
vation therapy and died 12.7 years after the diagnosis 
of the disease. One patient had bone metastases. Both 
patients had a medium risk at the time of diagnosis. 
Currently, the largest multicenter prospective study, 
the Prostate Cancer Research International: Active 
Surveillance (PRIAS) study, has been launched in 17 
countries with much stricter entry criteria (T1c-T2b, 
Table 2. Preoperative criteria for low risk prostate cancer
Study (authors) Criteria
Epstein et al.21 cT1c-2, Gleason score ≤6, PSAD ≤0.15 ng/mL/mL, 2 and less positive biopsy cores, <50% cancer in the core 
Bastian et al.22 cT1c-2, Gleason score ≤6, PSAD ≤0.15 ng/mL/mL, 2 and less positive biopsy cores, <50% cancer in the core
Klotz et al.23 PSA ≤10 ng/mL, Gleason score ≤6
D’Amico et al.18 cT2a, PSA ≤10 ng/mL, Gleason score ≤6 
Patel et al.24 cT2, Gleason score ≤7 
Soloway et al.25 cT2, Gleason score ≤6, PSA ≤0.15 ng/mL, 2 and less positive biopsy cores, <50% cancer in the core
Van den Bergh et al. (PRIAS)26 T1c-T2b, Gleason score ≤6, PSA ≤10 ng/mL, PSAD ≤0.20 ng/mL/mL, 2 and less positive cores 
Van As et al.27 cT1-T2a, PSA ≤15 ng/mL, Gleason score ≤7(3+4), ≤50% positive cores 
Dall’Era et al.28 PSA ≤10 ng/mL, Gleason score ≤6, ≤33% positive biopsy cores, <50% cancer in the core
PSA = prostate-specific antigen; PSAD = prostate-specific antigen density
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Gleason score ≤6, PSA ≤10 ng/mL, PSAD ≤0.20 ng/
mL/mL, and 2 or less positive biopsy cores)30. Follow 
up (median 1.6 years) is still short and the results of 
the study are immature, thus it is too early to draw any 
conclusions.
It is obvious that modern tools to distinguish indo-
lent, low risk and aggressive disease require improve-
ment31. The use of new biomarkers and their combina-
tions in the future could solve this problem. The Early 
Detection Research Network of the National Cancer 
Institute conducts a research for this purpose32. A 
promising research comes from prostate cancer im-
aging, particularly in the field of magnetic resonance 
imaging33,34.
Conclusion
Paucity of high-quality studies and their contra-
dictory results hamper clinicians’ selection of optimal 
treatment for patients with localized prostate cancer. 
Early diagnosis and successful treatment are certainly 
responsible for a mortality decline by 40% in some 
countries. The problem is that such a result comes 
at a high cost. A large number of people need to be 
tested, a significant part of them biopsied and a non-
negligible number treated to prevent one death from 
prostate cancer. Results of these studies suggest that 
in patients younger than 65 whose prostate cancer was 
diagnosed not only based on PSA but also by positive 
digital rectal examination, active treatment can bring 
cure, so it is necessary and advisable. Results are less 
certain in patients older than 65 or those with sig-
nificant comorbidity or life expectancy of less than 10 
years. Considering tumor differentiation, it appears to 
be a reasonable option to offer active treatment to me-
dium risk and high risk patients, taking into account 
the fact that the results of SPCG-4 do not support 
the latter category. In low risk tumors, benefit from 
aggressive treatment is dubious because the SPCG-4 
and PIVOT studies showed no reduction in mortal-
ity for this group, and the questionable benefits must 
be compared with the complications that such an ap-
proach carries, such as change in the quality of life of 
patients who did not need treatment. Looking at the 
absolute number of patients that fall into this catego-
ry, this problem becomes one of the burning problems 
of the contemporary treatment of this disease. Active 
surveillance is the legitimate approach for patients 
at low and very low risk, noting that the problem of 
proper patient classification exists and is well known, 
but that the results in properly selected patients are 
encouraging. Caution is needed in younger people. 
Neither inclusion criteria nor follow up protocols are 
unique, and there is still no agreement about them, 
whereas the follow up period in current studies is still 
too short. News in the field of imaging and new tu-
mor markers could bring significant change in the ap-
proach to this issue.
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Sažetak
NISKORIZIČNI RAK PROSTATE: AKTIVNO LIJEČENJE ILI AKTIVNI NADZOR?
I. Tomašković
Široka uporaba za prostatu specifičnog antigena (PSA) rezultirala je otkrivanjem potencijalno smrtonosnih karcinoma 
prostate u nižem, lječivom stadiju te je povezana sa značajnim padom smrtnosti od raka prostate. Unatoč činjenici da je 
rak prostate jedna od najsmrtonosnijih malignih bolesti u muškaraca, pojava osjetljivih dijagnostičkih testova također je 
rezultirala otkrivanjem karcinoma niskog rizika zbog visoke učestalosti latentnog raka prostate u muškaraca starije dobi i 
dugog prirodnog tijeka bolesti. Dakle, pojavio se i problem pretjeranog dijagnosticiranja indolentne bolesti i posljedičnog 
suvišnog liječenja. Kod šest puta više ljudi će biti dijagnosticirana bolest nego što će ih umrijeti od nje. Aktivni nadzor 
pojavio se kao odgovor na jasno dokumentirani rizik pretjerane dijagnoze i pretjeranog liječenja kod lokaliziranog raka 
prostate niskog rizika. To podrazumijeva početno praćenje s odgodom “pristupa s namjerom liječenja” dok se ne pojave 
dokazi povećanog rizika za progresiju bolesti. Ovaj pristup pokušava uravnotežiti rizike i nuspojave pretjeranog liječenja 
u odnosu na mogućnost napredovanja bolesti i izgubljenu priliku za liječenje. Sustavni pregled literature donosi današnje 
spoznaje o ovoj temi.
Ključne riječi: Prostata, tumori – dijagnostika; Rano otkrivanje tumora – standardi; Stanovništvo, praćenje; Antigen speci-
fičan za prostatu; Patologija – standardi 
